MedTrace Logo

A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors

NCT06990698 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-10-02

No results posted yet for this study

Summary

The goal of the phase 1 study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics activity of FP008 in subjects with advanced solid tumors.

Conditions

Interventions

DRUG

FP008 for injection

FP008 should be administered intravenous weekly. Six FP008 dose levels are planned to evaluated.

Sponsors & Collaborators

  • Zhuhai Fapon Biopharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Aung Naing, MD · The University of Texas MD Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-12
Primary Completion
2028-05-31
Completion
2028-09-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06990698 on ClinicalTrials.gov